Abstracts tagged "interstitial lung disease"

Abstract Number: 874 • 2019 ACR/ARP Annual Meeting
Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features
Iazsmin Ventura¹, Anisha Dua ², Ayodeji Adegunsoye ³, Mary Strek ³, James Curran ¹, Alexandra Weiss ¹ and Jonathan Chung ¹, ¹University of Chicago, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Chicago, Department of Pulmonary and Critical Care, Chicago
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized…
Abstract Number: 1834 • 2019 ACR/ARP Annual Meeting
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Ning Li ², Elizabeth Volkmann ³, Maureen Mayes ¹, Jun Ying ⁴, Michael Roth ⁵, Philip Clements ², Daniel Furst ⁶, Dinesh Khanna ⁷, Jonathan Goldin ², Robert Elashoff ² and Donald Tashkin ², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴University of Texas McGovern Medical School at Houston, Houston, TX, ⁵University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶University of California, Los Angeles, CA, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Response to immunosuppression is highly variable in systemic sclerosis (SSc) related interstitial lung disease (ILD), and there are no widely accepted clinical or biological…
Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Cosimo Bruni¹, Mariaelena Occhipinti ², Gianna Camiciottoli ³, Maurizio Bartolucci ⁴, Michael Pienn ⁵, Gemma Lepri ¹, Alessio Fabbrizzi ³, Alessandra Tottoli ¹, Giulia Ciardi ³, Dilia Giuggioli ⁶, Giovanna Cuomo ⁷, Francesco Masini ⁷, Andrea Olschewski ⁵, Federico Lavorini ³, Stefano Colagrande ⁸ and Marco Matucci-Cerinic ⁹, ¹Dept. Experimental and Clinical Medicine, Division of Rheumatology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ²Dept. Experimental and Clinical Medicine, Div. Pneumology and Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ³Dept. Experimental and Clinical Medicine, Div. Pneumology, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁴Dept. of Services, Div. Emergency-Urgency Radiology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, ⁵Ludwig Boltzmann Institute for Lung Vascular Research, Institute of Physiology, Medical University of Graz, Graz, Austria, ⁶Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Modena, Italy, ⁷Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy, ⁸Dept. Experimental and Clinical Medicine, Div. Radiology II, Azienda Ospedaliera Universitaria Careggi – University of Florence, Florence, Italy, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…
Abstract Number: 962 • 2019 ACR/ARP Annual Meeting
The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Erin Wilfong¹, Jennifer Young-Glazer ², Elise Rizzi ³, Rosemarie Dudenhofer ², Leslie Crofford ¹ and Peggy Kendall ², ¹Vanderbilt University, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville
Background/Purpose: Systemic sclerosis (SSc) is a severe systemic disease characterized by fibrosis of the skin and visceral organs. While protein biomarkers of lung damage, e.g.…
Abstract Number: 2066 • 2019 ACR/ARP Annual Meeting
Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience
Michael Allen¹, Emily Press ¹, Aditi Mathur ¹, Sakshi Dua ², Maria Padilla ² and Ioannis Tassiulas ², ¹Icahn School of Medicine at Mt Sinai, New York, ²Icahn School of Medicine, New York
Background/Purpose: Interstitial lung disease (ILD) encompasses a group of disorders that are classified together based on similar clinical, radiographic and pathologic findings. ILD is highly…
Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Mirette Habib¹, Sara Jaafar ¹, Annie Park ¹, Suiyuan Huang ¹, Wen Ye ¹, Vivek Nagaraja ¹, Eric White ¹, Kevin Flaherty ² and Dinesh Khanna ³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
Abstract Number: 2135 • 2019 ACR/ARP Annual Meeting
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Marco Sebastiani¹, Giulia Cassone ², Caterina Vacchi ¹, Lisa De Pasquale ¹, Stefania Cerri ³, Giovanni Della Casa ⁴, Carlo Salvarani ¹ and Andreina Manfredi ¹, ¹Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, MOdena, Emilia-Romagna, Italy, ²Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy, ³Respiratory Disease Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁴Radiology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy
Background/Purpose: Recently the term “interstitial pneumonia with autoimmune features” (IPAF) has been proposed to identify patients with interstitial lung disease and autoimmune characteristics, not fulfilling…
Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Bret Sohn¹, Erin Wilfong ¹ and Leslie Crofford ¹, ¹Vanderbilt University, Nashville
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
Abstract Number: 2141 • 2019 ACR/ARP Annual Meeting
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Kristin D'Silva¹, Marcy Bolster ¹, Flavia Castelino ², Amita Sharma ¹, Brent Little ¹, Sydney Montesi ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Harvard University, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue diseases (CTD). Approximately one-third of patients with…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 189 • 2019 ACR/ARP Annual Meeting
Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Tracy J. Doyle ², Hemin Lee ³, Yinzhu Jin ³, Angela Y. Tong ³, Adrian J. Santiago Ortiz ³, Jeffrey Sparks ⁴ and Seoyoung C. Kim ³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The prevalence of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patient ranges between 5-10%. ILD leads to high morbidity and mortality in patients…
Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Aryeh Fischer¹, Oliver Distler ², Dinesh Khanna ³, Yannick Allanore ⁴, Anna Maria Hoffmann-Vold ⁵, Gabriele Valentini ⁶, Toby Maher ⁷, Martin Aringer ⁸, Leslie Meng ⁹, Margarida Alves ¹⁰, Martina Gahlemann ¹¹, Manuel Quaresma ¹⁰ and Masataka Kuwana ¹², ¹University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ⁷National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
Abstract Number: 2298 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis
Raul Castellanos-Moreira¹, Sebastian Rodriguez-Garcia ², Virginia Ruiz-Esquide ³, Fernanda Hernández-González ⁴, Marcelo Sánchez ⁵, José Ramírez ⁶, Mariana Benegas ⁵, Carmen Lucena-Pozo ⁴, Carlos Agustí ⁴, Marc Boada ⁷, Odette Viñas ⁸, Estíbaliz Ruiz ⁸, Sergio Prieto-González ⁹, Jose Gomez-Puerta ¹, Jacobo Sellares ⁴, Juan Cañete ¹, Isabel Haro ¹⁰ and Raimon Sanmarti ¹, ¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁷Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].